Papadimitriou acted as Chief Development Officer at iOmx from 2017 until mid of 2019. Before joining iOmx, he acted as Global Head Large Molecule Bioanalytical R&D and Pharmaceutical Sciences Site Head at Roche Innovation Center Munich. During his career at Roche, starting in 1997, Apollon held several leadership positions in Biologics R&D within Pharma Research and Early Development. Papadimitriou is a biologist by training and earned his PhD in Biochemistry in 1995 from the Julius-Maximilians-University of Würzburg, Germany. After a post-doctorate at the Institute for Experimental Cancer Research in Freiburg, Germany, he started his industrial career at Boehringer Mannheim in 1996 as a Senior Scientist in Biotechnology Research.

iOmx Therapeutics is a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets. iOmx was founded in 2016 and is based in Martinsried/Munich.

At the same time, the company made a number of changes to the executive management team. iOmx appointed Marcus Irsfeld Chief Financial Officer, and Aratana Therapeutics CEO Steven St. Peter was elected to chairman of iOmx’ Supervisory Board. Henrijette Richter of Sofinnova has assumed the role of vice chairman of the Supervisory Board. Patrick A. Baeuerle, co-founder and scientific advisor of iOmx, has been called as a new member of the Supervisory Board.